Epiminder: Trading Update
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The DETECT study evaluates the Minder System for improving clinical decision-making in epilepsy patients after inconclusive EEG assessments. An investor webinar is scheduled to provide updates on the company's progress since its IPO.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-update-1104
Earlier from Epiminder
- DETECT Study reaches 25th enrolment as momentum builds
- 1H FY26 Results Presentation
- 1H FY26 Results Announcement
- 1HFY26 Appendix 4D and Financial Report
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Epiminder
- FY26 Investor Presentation
- FY26 Appendix 4E and Annual Report
- 75th DETECT Enrollee
- 100th patient enrolled in US study ahead of schedule
- FY27 YTD operational update and AGM materials
Follow Epiminder into a list and get an email when it puts out news.
Follow Epiminder